Study designs of evaluations included in the review
The review was restricted to randomised placebo-controlled trials (RCTs).
Specific interventions included in the review
The included trials had to compare megestrol acetate with placebo. The doses ranged from 40 to 480 mg/day. The duration of follow-up ranged from 8 to 80 weeks.
Participants included in the review
Specific inclusion criteria were not given, but the trials appeared to be concerned with cancer patients with cachexia.
Outcomes assessed in the review
The outcome assessed was weight gain, expressed as the difference in weight at the start of treatment compared with that at the end. Trials that expressed weight gain only as a percentage were excluded unless the authors provided suitable information for the calculation of weight gain.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the reviewers performed the selection.